Antibody Drug Conjugate Brands

Prescription antibody-drug conjugate treatment for classical Hodgkin lymphoma and CD30-expressing peripheral T-cell lymphomas, co-developed by Seagen and licensed to Takeda Pharmaceutical.

Roche's HER2-targeted antibody-drug conjugate (ado-trastuzumab emtansine, T-DM1) developed by Genentech using ImmunoGen's DM1 cytotoxic technology, FDA approved February 22, 2013, for HER2-positive metastatic breast cancer and later for early-stage HER2-positive breast cancer following the KATHERINE trial.